Edwards Lifesciences announced the CE marking of the SAPIEN M3 mitral valve replacement system for the treatment of patients with moderate to and severe mitral regurgitation on 14 April.
The regulatory approval makes Edwards the “only company providing a transcatheter portfolio that includes both replacement and repair treatment options...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?